IOL Chemicals & Pharmaceuticals Ltd
IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market.[1]
It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%.[2]
- Market Cap ₹ 2,658 Cr.
- Current Price ₹ 90.7
- High / Low ₹ 127 / 57.5
- Stock P/E 25.3
- Book Value ₹ 57.5
- Dividend Yield 0.88 %
- ROCE 8.87 %
- ROE 6.13 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 20.6%
Cons
- Company has a low return on equity of 8.05% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| 2,184 | 2,217 | 2,133 | 2,079 | 2,129 | |
| 1,925 | 1,991 | 1,902 | 1,877 | 1,915 | |
| Operating Profit | 259 | 226 | 231 | 202 | 213 |
| OPM % | 12% | 10% | 11% | 10% | 10% |
| 17 | 25 | 30 | 22 | 22 | |
| Interest | 8 | 16 | 16 | 15 | 17 |
| Depreciation | 43 | 46 | 63 | 72 | 75 |
| Profit before tax | 225 | 189 | 182 | 138 | 144 |
| Tax % | 25% | 26% | 26% | 27% | |
| 168 | 139 | 134 | 101 | 105 | |
| EPS in Rs | 5.71 | 4.74 | 4.58 | 3.44 | 3.58 |
| Dividend Payout % | 14% | 17% | 22% | 23% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -2% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -17% |
| TTM: | -11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | -8% |
| 3 Years: | 7% |
| 1 Year: | 11% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 8% |
| Last Year: | 6% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Equity Capital | 59 | 59 | 59 | 59 |
| Reserves | 1,334 | 1,449 | 1,553 | 1,629 |
| 44 | 80 | 33 | 117 | |
| 526 | 435 | 600 | 577 | |
| Total Liabilities | 1,962 | 2,022 | 2,244 | 2,382 |
| 561 | 752 | 933 | 1,171 | |
| CWIP | 105 | 90 | 101 | 22 |
| Investments | 2 | 20 | 20 | 21 |
| 1,294 | 1,161 | 1,190 | 1,169 | |
| Total Assets | 1,962 | 2,022 | 2,244 | 2,382 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 93 | 122 | 290 | 179 | |
| -121 | -120 | -191 | -154 | |
| -2 | -4 | -92 | 46 | |
| Net Cash Flow | -29 | -2 | 6 | 70 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 79 | 83 | 81 | 90 |
| Inventory Days | 95 | 77 | 111 | 95 |
| Days Payable | 95 | 74 | 123 | 112 |
| Cash Conversion Cycle | 79 | 86 | 69 | 73 |
| Working Capital Days | 71 | 72 | 71 | 58 |
| ROCE % | 14% | 12% | 9% |
Documents
Announcements
-
Board Meeting Intimation for Notice Of Board Meeting
4 Nov - Board meeting on 11 Nov 2025 to approve unaudited Q2/H1 results; trading window reopens 14 Nov.
-
EDQM Issued CEP Certificate For 'Sitagliptin Phosphate Monohydrate'
27 Oct - EDQM issued CEP for Sitagliptin Phosphate Monohydrate on 27 October 2025.
-
Intimation Of Incorporation Of Wholly Owned Subsidiary
24 Oct - Incorporated IOL Pharmaxis UK Limited on October 16, 2025; share capital GBP10,000; 100% owned.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 18 Oct
-
EDQM Issued CEP Certificate For 'Pantoprazole Sodium Sesquihydrate Process-III'
15 Oct - EDQM issued CEP for Pantoprazole Sodium Sesquihydrate Process-III on 14 Oct 2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT REC
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT
-
May 2023TranscriptNotesPPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Mar 2021Transcript PPT
-
Dec 2020Transcript PPT
-
Nov 2020TranscriptNotesPPT
Business Segments